Breaking News Instant updates and real-time market news.

CTRP

Ctrip.com

$40.99

-0.88 (-2.10%)

, TGT

Target

09:26
11/25/16
11/25
09:26
11/25/16
09:26

On The Fly: Pre-market Movers

HIGHER: Ctrip.com (CTRP), up 10.6% after reporting better than expected Q3 revenue and earnings and announcing an agreement to acquire Skyscanner after the closing bell on Wednesday... Macy's (M), up 0.9%, Target (TGT), up 0.9%, Wal-Mart (WMT), up 0.6%, J.C. Penney (JCP), up 1.7%, amid media reports casting a positive light on early holiday shopping trends on Black Friday. LOWER: Airgain (AIRG), down 14% after it announced the release of lock up restrictions with Northland in connection with the company's initial public offering.

CTRP

Ctrip.com

$40.99

-0.88 (-2.10%)

TGT

Target

WMT

Wal-Mart

M

Macy's

JCP

J.C. Penney

AIRG

Airgain

$26.95

0.2 (0.75%)

  • 01

    Dec

CTRP Ctrip.com
$40.99

-0.88 (-2.10%)

11/25/16
BMUR
11/25/16
NO CHANGE
Target $54
BMUR
Buy
Ctrip.com represents unique investment opportunity, says Brean Capital
Brean Capital analyst Fawne Jiang said Ctrip.com represents a unique opportunity for investors. The analyst sees a number of levers in the business model that appear to be ready to play out in the coming years, including consolidation in the domestic travel market, strategic investments in overseas resources, its acquisition of Skyscanner, and a strengthening of its market leading position in China. Jiang reiterated her Buy rating and raised her price target to $54 from $52 on Ctrip shares.
11/25/16
SBSH
11/25/16
NO CHANGE
Target $55
SBSH
Buy
Ctrip.com strengthening position in global travel market, says Citi
Citi analyst Alicia Yap views Ctrip.com's Q3 results as "solid" and keeps a Buy rating on the shares with a slightly reduced price target of $55. The company, after dominating the China online travel booking landscape, is "stepping up its positioning" in the global online travel market via recent acquisitions, Yap tells investors in a research note. Ctrip has enhanced its global product offerings for both air and hotels, the analyst contends.
11/25/16
JPMS
11/25/16
NO CHANGE
Target $55
JPMS
Overweight
JPMorgan turning more positive on Ctrip.com outlook
JPMorgan analyst Alex Yao says he's turning more positive on Ctrip.com's profit outlook following the company's Q3 results. The company's operating efficiency is improving while Qunar is turning profitable, Yao tells investors in a research note. The analyst views the Skyscanner acquisition as "solid progress" toward expanding into the addressable market for the outbound travel business. He maintains an Overweight rating on Ctrip.com with a $55 price target. The Chinese travel service provider is up $3.51 to $44.50 in pre-market trading.
11/25/16
HSBC
11/25/16
UPGRADE
HSBC
Buy
Ctrip.com upgraded to Buy from Hold at HSBC (yesterday)
TGT Target

09/16/16
FBCO
09/16/16
INITIATION
Target $65
FBCO
Neutral
Target coverage assumed with a Neutral at Credit Suisse
Credit Suisse analyst Edward Kelly assumed coverage on Target with a $65 price target, down from $72, citing an uncertain outlook, structural headwinds, and under investment.
09/16/16
09/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoPro (GPRO) initiated with a Buy at BofA/Merrill. 2. JetBlue (JBLU) initiated with an Outperform at Imperial Capital. 3. PepsiCo (PEP), Dr Pepper Snapple (DPS), and Monster Beverage (MNST) were initiated with an Outperform at Credit Suisse, while the firm initiated Boston Beer (SAM) with an Underperform. Credit Suisse also initiated Coca-Cola (KO) and Constellation Brands (STZ) with a Neutral. 4. lululemon (LULU) initiated with a Positive at Susquehanna. 5. Target (TGT) coverage assumed with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
BOFA
09/23/16
NO CHANGE
Target $55
BOFA
Buy
BofA thinks Verizon deal stays on track despite Yahoo data breach
Bank of America Merrill Lynch analyst Justin Post said that Yahoo's (YHOO) disclosure of the massive data breach impacting over 500M of its users is clearly a negative for the company that could result in email account closures, but he does not anticipate a major impact on Yahoo's business related to this breach, citing as evidence the fact that he is not aware of any significant business impairment or financial liability related to security breaches at LinkedIn (LNKD) in 2012 and at eBay (EBAY) in 2014. Post adds that the Target (TGT) data breach, which did include credit card info, is not directly comparable to Yahoo's breach. For Verizon (VZ) to back out of its acquisition agreement, Post thinks the company would need to assume Yahoo acted in bad faith during negotiations and that the Yahoo asset is impaired or comes with significant liability, neither of which he sees as being the case. The analyst keeps a Buy rating on Yahoo and bumped his target on the shares to $55 from $53, citing an increased price target on Alibaba (BABA) that a peer at the firm recently set.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Target initiated with a Neutral at Guggenheim
WMT Wal-Mart

11/23/16
UBSW
11/23/16
NO CHANGE
Target $100
UBSW
Buy
Dollar Tree price target raised to $100 from $90 at UBS
UBS analyst Michael Lasser raised his price target on Dollar Tree (DLTR) to $100 from $90 following Q3 results. The analyst said the company's results eased a number of fears and demonstrated it could hold its own against competitors such as Wal-Mart (WMT). Dollar Tree exhibited comp growth, and its merger with Family dollar is providing synergies within its guidance, said Lasser, who reiterated his Buy rating on the shares.
11/17/16
BARD
11/17/16
NO CHANGE
Target $80
BARD
Outperform
Wal-Mart strategy remains on track, says Baird
Baird analyst Peter Benedict notes that this was a 'noisy' quarter for Wal-Mart, but underlying EPS effectively in line with expectations. While acknowledging that U.S. traffic gains slowed against a tougher compare and Q4 EPS guidance was viewed as a disappointment, the analyst believes Wal-Mart's strategy remains on track and 2017 EPS estimates appear largely de-risked. He reiterates an Outperform rating and $80 price target on the shares, given the company's defensive appeal within a still choppy consumer/retail backdrop.
10/27/16
JPMS
10/27/16
DOWNGRADE
Target $28
JPMS
Neutral
JPMorgan downgrades Vitamin Shoppe on 2017 earnings risk
JPMorgan analyst Christopher Horvers earlier today downgraded Vitamin Shoppe (VSI) to Neutral from Overweight and lowered his price target for the shares to $28 from $33. The analyst sees downside risk to 2017 earnings as the competitive environment worsens. GNC Holdings (GNC) under new management is testing major pricing and loyalty card changes while Vitamin Shoppe's comparable prices are higher versus Amazon (AMZN), Horvers tells investors in a research note. He sees Vitamin Shoppe "squeezed between" its three larger competitors, GNC, Wal-Mart (WMT) and Amazon. The stock is trading down $2.05 to $25.30 following GNC's Q3 results. GNC is trading down 20% to $16.04.
11/11/16
BARD
11/11/16
NO CHANGE
Target $80
BARD
Outperform
Wal-Mart 2017 earnings somewhat de-risked, says Baird
Baird analyst Peter Benedict expects Wal-Mart's Q3 results to be generally in-line as investments in associates, processes, and prices are working together to drive improved customer satisfaction and sales. The company's 2017 estimates appear to be de-risked as management reset margin and earnings expectations at last month's investor meeting, said Benedict, who reiterated his Outperform rating and $80 price target on Wal-Mart shares.
M Macy's

10/31/16
DBAB
10/31/16
UPGRADE
Target $45
DBAB
Buy
Macy's upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Paul Trussell upgraded Macy's (M) to Buy saying he expects the retailer to regain earnings momentum ahead of peers while the valuation "looks cheap." The analyst thinks Macy's margins will surprise to the upside. He raised his price target for the shares to $45 from $40. Trussell coupled the upgrade with a downgrade of Nordstrom (JWN) to Hold.
09/30/16
GUGG
09/30/16
INITIATION
Target $45
GUGG
Buy
Macy's initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Macy's with a Buy and a $45 price target saying shares offer a compelling risk reward ratio due to the company's healthy balance sheet, 4.2% dividend yield, and strong free cash flow.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
OTRG
11/02/16
UPGRADE
OTRG
Mixed
Macy's upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Macy's to Mixed saying checks exceeded goals for 7 out of 8 vendors driven by improved product and merchandising.
JCP J.C. Penney

11/11/16
BARD
11/11/16
NO CHANGE
Target $13
BARD
Outperform
J.C. Penney longer-term recovery story intact, says Baird
Baird analyst Mark Altschwager notes that J.C. Penney reported weaker than expected Q3 comps and gross margin but reaffirmed longer-term growth targets. While the analyst is encouraged by tight cost controls amid the sluggish growth backdrop, he will need to see comps regain momentum to support longer-term goals. Nonetheless, Altschwager continues to believe the pieces are in place for this to happen, setting up attractive risk/reward as this self-help recovery story unfolds. He reiterates an Outperform rating and $13 price target on the shares.
09/01/16
RILY
09/01/16
NO CHANGE
RILY
B. Riley adds J.C. Penney, Marvell to Focus List
B. Riley updated its Focus List for the month of September by adding J.C. Penney (JCP) and Marvell Technology (MRVL) while removing Intersil (ISIL).
10/03/16
RILY
10/03/16
NO CHANGE
RILY
PFSweb, Sanmina added to Focus List, J.C. Penney, Transact deleted at B. Riley
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
J.C. Penney initiated with a Neutral at Guggenheim
AIRG Airgain
$26.95

0.2 (0.75%)

09/06/16
NORL
09/06/16
INITIATION
Target $15
NORL
Outperform
Airgain initiated with an Outperform at Northland
Northland analyst Tom Sepenzis initiated Airgain with an Outperform rating and $15 price target.
09/21/16
WDLK
09/21/16
DOWNGRADE
Target $14
WDLK
Hold
Airgain downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Matthew Robison downgraded Airgain to Hold with a $14 price target following the company's Q2 results.
10/31/16
WDLK
10/31/16
UPGRADE
Target $16
WDLK
Buy
Airgain upgraded to Buy on recent pullback at Wunderlich
Wunderlich analyst Matthew Robison upgraded Airgain to Buy from Hold saying the recent pullback in shares has created an attractive entry point. The company's business continues to progress, Robison tells investors in a research note. He raised his price target for the shares to $16 from $14.
10/31/16
WDLK
10/31/16
UPGRADE
WDLK
Buy
Airgain upgraded to Buy from Hold at Wunderlich
Wunderlich analyst Matthew Robison upgraded Airgain to Buy.

TODAY'S FREE FLY STORIES

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.